← Eichor
Condition: Locally Advanced Urothelial Carcinoma Synced from ClinicalTrials.gov · July 28, 2026

Recruiting studies: Locally Advanced Urothelial Carcinoma

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Chemotherapy and Sequential Immunotherapy for Locally Advanced Urothelial Cancer
Phase 2 · 4 location(s) · Erasmus Medical Center · NCT05600127Postoperative Adjuvant Immunotherapy Combined with Radiotherapy Versus Surgery Alone in Locally Advanced UTUC
Phase N/A · 2 location(s) · Peking University First Hospital · NCT06598761Safety and Tolerability of TNG462 in Patients With MTAP-deleted Solid Tumors
Phase 1/Phase 2 · 26 location(s) · Tango Therapeutics, Inc. · NCT05732831Cabozantinib in Combination With Enfortumab Vedotin for Locally Advanced or Metastatic Urothelial Cancer
Phase 1 · 1 location(s) · Emory University · NCT04878029Consolidative Local Therapy (CLT) in Oligo-metastatic Urothelial Carcinoma
Phase 2 · 1 location(s) · Yale University · NCT07048457Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma
Phase 1 · 10 location(s) · Nammi Therapeutics Inc · NCT06582017A Safety Study of Enfortumab Vedotin in Indian Adults With Urothelial Cancer
Phase 4 · 13 location(s) · Astellas Pharma Global Development, Inc. · NCT06862219AVENTINE-1: Study of AVZO-1418 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metasta
Phase 1/Phase 2 · 18 location(s) · Avenzo Therapeutics, Inc. · NCT07038343A Study of [225Ac]Ac-AKY-1189 in Patients With Solid Tumors
Phase 1 · 12 location(s) · Aktis Oncology, Inc. · NCT07020117A Study to Evaluate the Safety, Pharmacokinetics, and Activity of Enzelkitug as a Single Agent and in Combination With C
Phase 1 · 41 location(s) · Genentech, Inc. · NCT05581004Dual-Target Nectin-4/HER2 CAR-NK Cells in Advanced Urothelial Carcinoma
Phase 1 · 1 location(s) · Beijing Biotech · NCT07492628A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2
Phase 2 · 221 location(s) · Seagen, a wholly owned subsidiary of Pfizer · NCT04879329A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract
Phase 3 · 286 location(s) · Eli Lilly and Company · NCT072183809MW2821 in Combination With Toripalimab vs Standard Chemotherapy in Locally Advanced or Metastatic Urothelial Cancer
Phase 3 · 1 location(s) · Mabwell (Shanghai) Bioscience Co., Ltd. · NCT06592326Trastuzumab in Combination With Serplulimab and Chemotherapy for the Treatment of HER2-overexpressing Unresectable Local
Phase 2 · 1 location(s) · Xiujuan Qu · NCT07506057Combined Postoperative Radiotherapy With Kidney Sparing Surgery for Locally Advanced High-risk Ureteral Cancer
Phase N/A · 2 location(s) · Xuesong Li · NCT06120387FORAGER-1: A Study of LOXO-435 (LY3866288) in Participants With Cancer With a Change in a Gene Called FGFR3
Phase 1 · 82 location(s) · Eli Lilly and Company · NCT05614739EV + Toripalimab vs GC as Neoadjuvant Therapy in Locally Advanced/High-Risk MIBC
Phase 2 · 1 location(s) · Peking University Third Hospital · NCT07647289A Study of BL-B01D1 + PD-1 in Patients With Locally Advanced or Metastatic Urothelial Carcinoma
Phase 2 · 1 location(s) · Sichuan Baili Pharmaceutical Co., Ltd. · NCT06405425Enfortumab Vedotin and Pembrolizumab in People With Bladder Cancer
Phase 2 · 10 location(s) · Memorial Sloan Kettering Cancer Center · NCT05239624A Study of ASP2998 Given by Itself and Given With Standard Therapies in People With Solid Tumors
Phase 1/Phase 2 · 7 location(s) · Astellas Pharma Global Development, Inc. · NCT07287995Clinical Trial of YH32364 in Patients With Locally Advanced or Metastatic EGFR Overexpressing Solid Tumors
Phase 1/Phase 2 · 4 location(s) · Yuhan Corporation · NCT06975410Clofarabine Therapy in Locally Advanced or Metastatic Urothelial Carcinoma
Phase 1/Phase 2 · 1 location(s) · Ekaterina Laukhtina · NCT07034053KEYMAKER-U04 Substudy 04D: A Clinical Study of New Treatments Given With Enfortumab Vedotin and Pembrolizumab in People
Phase 1/Phase 2 · 16 location(s) · Merck Sharp & Dohme LLC · NCT07232602A Phase III Study of SHR-A2102 Versus Investigator-selected Therapy in Advanced Urothelial Carcinoma
Phase 3 · 1 location(s) · Shanghai Hengrui Pharmaceutical Co., Ltd. · NCT06738251Gemcitabine and Carboplatin After Progression on Enfortumab Vedotin and Pembrolizumab in Advanced/Metastatic Urothelial
Phase 2 · 2 location(s) · Fox Chase Cancer Center · NCT07043972Circulating and Urine Tumor DNA Dynamics Predict Minimal Residual Disease and Recurrence Risk in Locally Advanced Upper
Phase N/A · 1 location(s) · RenJi Hospital · NCT05595408Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Loc
Phase 1/Phase 2 · 18 location(s) · Aulos Bioscience, Inc. · NCT05267626A Substudy of Investigational Agents in Programmed Cell Death-1/Ligand 1 (PD-1/L1) Refractory Locally Advanced or Metast
Phase 1/Phase 2 · 28 location(s) · Merck Sharp & Dohme LLC · NCT05562830A Study to Evaluate 9MW2821 Versus Chemotherapy in Subjects With Previously Treated Locally Advanced or Metastatic Uroth
Phase 3 · 1 location(s) · Mabwell (Shanghai) Bioscience Co., Ltd. · NCT06196736
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.